|
Home
| Table B33a. Results (pg/g [pptr] wet weight) of triplicate
analyses for 2,3,7,8-substituted PCDD congeners in tautog muscle composites
(Station TA1; nd = <MDL) |
Composite
# |
Congener |
2,3,7,8-
TCDD |
1,2,3,7,8-
PeCDD |
1,2,3,4,7,8-
HxCDD |
1,2,3,6,7,8-
HxCDD |
1,2,3,7,8,9-
HxCDD |
1,2,3,4,6,7,8-
HpCDD |
OCDD |
| 144 |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
| 144-dup. |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
| 144-trip.a |
|
|
|
|
|
|
|
| Mean |
|
|
|
|
|
|
|
| Std. dev. |
|
|
|
|
|
|
|
| RPDb |
|
|
|
|
|
|
|
| |
| MDL |
1.6 |
7.3 |
3.1 |
3.4 |
11 |
6.5 |
4.0 |
aTriplicate results not included due to 8-fold
dilution required for analysis. RPD reported instead.
bRPD (relative percent difference) for duplicate analyses = (100
x absolute value for range)/mean. |
| Table B33b. Results (pg/g
[pptr] wet weight) of triplicate analyses for 2,3,7,8-substituted PCDF
congeners in tautog muscle composites (Station TA1; nd = <MDL) |
Composite
# |
Congener |
2,3,7,8-
TCDFa |
1,2,3,7,8-
PeCDF |
2,3,4,7,8-
PeCDF |
1,2,3,4,7,8-
HxCDF |
1,2,3,6,7,8-
HxCDF |
1,2,3,7,8,9-
HxCDF |
2,3,4,6,7,8-
HxCDF |
1,2,3,4,6,7,8-
HpCDF |
1,2,3,4,7,8,9-
HpCDF |
OCDF |
| 144 |
1.7 |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
| 144-dup. |
1.4 |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
nd |
| 144-trip.b |
|
|
|
|
|
|
|
|
|
|
| Mean |
1.6 |
|
|
|
|
|
|
|
|
|
| Std. dev. |
0.2 |
|
|
|
|
|
|
|
|
|
| RPDc |
19.1 |
|
|
|
|
|
|
|
|
|
| |
| MDL |
1.1 |
7.7 |
8.7 |
4.1 |
2.5 |
10 |
4.0 |
5.7 |
12 |
28 |
aValue for 2,3,7,8-TCDF in Batch
3 is taken from "DB-Dioxin" second-column
confirmation.
bTriplicate results not included due to 8-fold dilution required
for analysis. RPD reported instead.
cRPD (relative percent difference) for duplicate analyses = (100
x absolute value for range)/mean. |
Table B34
|